ClinicalTrials.gg
RecruitingNCT06236048EAGLESUpdated Sep 5, 2025

Energetics and Glutamate in Schizophrenia

An observational study in Schizophrenia, sponsored by King's College London. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-05.

Sponsored by King's College London · Observational

How we know

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
75
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Schizophrenia by King's College London — 8 open to participants now, 8 under way, none of them phase 3. Schizophrenia · King's College London.

Started
2024
with 1 other
Observational
4 of 20
4 open now
Registered
12th of 20
by date

Among the 20 studies in Schizophrenia by King's College London, this one is one of 2 that started in 2024, is one of 4 observational ones, and was the 12th registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

8 of the 20 studies in Schizophrenia by King's College London are open now, in 3 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Schizophrenia by King's College London, or all of them as a file.
02

Study summary

The goal of this case-control study is to compare brain glutamate, glucose utilisation, lactate production and brain activity in healthy volunteers and people with a diagnosis of schizophrenia.

It investigates the following main questions:

Whether, compared to healthy volunteers, participants with schizophrenia show:

  1. reduction in brain glucose utilisation
  2. increased brain lactate
  3. greater variability in brain glutamate

Participants will be asked to have a screening visit, a MRI brain scan and a PET-MRI brain scan.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

healthy volunteers - community sample people with a diagnosis of schizophrenia - clinical mental health teams.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Healthy volunteer group:

1. No history of psychiatric illness, as assessed on the Mini neuropsychiatric Interview (MINI).

Treatment responsive schizophrenia group:

  1. Meeting ICD-11 criteria for schizophrenia (F20)
  2. Meeting symptomatic consensus criteria for remission, defined as scores of mild or less on items P1, P2, P3, N1, N4, N6, G5 and G9 of the PANSS and no history of symptomatic relapse in the past 6 months.
  3. Currently receiving one or more of the following antipsychotic medications: Olanzapine; Risperidone; Quetiapine; Amisulpride; Aripiprazole; Paliperidone.
  4. Antipsychotic adherent, defined as having a score of >=moderate adherence on the Kemp scale.

Treatment-resistant schizophrenia group:

  1. Meeting ICD-11 criteria for schizophrenia (F20)
  2. Meeting modified consensus criteria for treatment resistance, including history of at least two antipsychotic treatment trials each lasting ≥6 weeks at a dose of ≥400mg chlorpromazine equivalents.
  3. Total PANSS total score > 70
  4. Moderate functional impairment (\<60 on the SOFAS)
  5. Currently receiving one or more of the following antipsychotic medications: Clozapine; Olanzapine; Risperidone; Quetiapine; Amisulpride; Aripiprazole; Paliperidone.
  6. Antipsychotic adherent, defined as having a score of >=moderate adherence on the Kemp scale.

Exclusion criteria

Exclusion Criteria:

All participants:

  1. Pregnancy or breastfeeding
  2. Lacking in mental capacity to provide to study participation.

2. Diabetes or history of taking an antidiabetic medication 3. Presence of to MRI at 7 Tesla, including metallic or electronic implants and dental wires.

4. Severe claustrophobia prohibiting participation on PET or MRI 5. Body size above the comfortable limits for the MRI scanner. 6. Previous participation in research or clinical procedure/s involving ionising radiation, which, including the current study, would result in total radiation exposure >=10mSv within 12 months 7. History of head injury resulting in loss of consciousness for > 5 minutes 8. Meeting ICD-11 criteria for organic mental disorder (F00-F09) 9. Meeting ICD-11 criteria for mental and behavioural disorders due to psychoactive substance use (F10-F19) 10. With exclusion of nicotine or cannabis, meeting ICD-11 criteria for psychoactive substance dependence 11. Participation in clinical trial investigating any pharmacological agent other than a licensed antipsychotic compound in the last month.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
75 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Healthy volunteers

    Procedure: MRI scan · Procedure: PET-MR scan

  • Schizophrenia - remission

    Procedure: MRI scan · Procedure: PET-MR scan

  • Treatment resistant schizophrenia

    Procedure: MRI scan · Procedure: PET-MR scan

Interventions

  • ProcedureMRI scan

    7 Tesla MRI scan

  • ProcedurePET-MR scan

    18F-fluorodeoxyglucose PET-MR scan

06

What researchers measure

Primary outcomes

  1. Brain glucose utilisation

    Measured using fully quantitative 18F-fluorodeoxyglucose PET (CMRglc)

    Time frame: 1 day

  2. Glutamate - anterior cingulate cortex

    Glutamate and glutamine measured using magnetic resonance spectroscopy at 7 Tesla

    Time frame: 1 day

  3. Lactate - visual cortex

    Measured using magnetic resonance spectroscopy at 7 Tesla at rest and during visual stimulation

    Time frame: 1 day

  4. Cerebral blood flow

    Measured using arterial spin labelling, 3 Tesla MRI

    Time frame: 1 day

  5. Cortical network activity

    Network activity / connectivity as measured using fMRI at 3 Tesla

    Time frame: 1 day

07

Study locations

1 of 1 sites recruiting
  • South London and the Maudsley NHS Foundation Trust
    London, United Kingdom
    Recruiting
    • Alice Egerton, PhD · Contact
08

References and documents

Individual participant data

Plan to share: Yes — After the end of the study pseudoanonymised data will be available to other researchers.

Supporting information: Study protocol

Time frame: After the primary analyses are completed and published.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2024 (actual). Primary completion is estimated for Dec 2027, 45 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2024
First posted
Feb 1, 2024
StartActual
Mar 4, 2024
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 1, 2028
Last update
Sep 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06236048
Responsible party
Sponsor
First posted
Feb 1, 2024
Start date
Mar 4, 2024
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 1, 2028 (estimated)
Last update
Sep 5, 2025

Study contacts

Alice Egerton, PhD
Contact
EAGLES_study@kcl.ac.uk
+442078480721

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion